- Treatment characteristics.
| Variables | n (%) |
|---|---|
| Surgery | |
| Radical retro pubic prostatectomy | 15 (5.3) |
| Radical perineal prostatectomy | 2 (0.7) |
| Transurethral resection of the prostate | 40 (14.2) |
| Unmentioned | 27 (9.6) |
| No surgery | 198 (70.2) |
| Radiotherapy | |
| External beam radiotherapy | 97 (34.4) |
| Brachytherapy | 1 (0.4) |
| No radiotherapy | 184 (65.2) |
| 1st-line treatment | |
| ADT | 176 (62.4) |
| ADT+bicalutamide | 27 (9.6) |
| ADT+abiraterone | 23 (8.2) |
| ADT+docetaxel | 8 (2.8) |
| ADT+enzalutamide | 7 (2.5) |
| ADT+cyproterone acetate | 3 (1.1) |
| No treatment received | 38 (13.5) |
| 2nd-line treatment | |
| ADT+abiraterone | 34 (12.1) |
| ADT+enzalutamide | 33 (11.7) |
| ADT+bicalutamide | 14 (5.0) |
| ADT+docetaxel | 11 (3.9) |
| ADT alone | 5 (1.8) |
| ADT+apalutamide | 1 (0.4) |
| ADT+cabazitaxel | 1(0.4) |
| No treatment received | 143 (50.8) |
| 3rd-line treatment | |
| No treatment received | 186 (66.0) |
| ADT+abiraterone | 20 (7.1) |
| ADT+enzalutamide | 14 (5.0) |
| ADT+docetaxel | 11 (3.9) |
| ADT alone | 4 (1.4) |
Values are presented as numbers and percentages (%).
ADT: androgen deprivation therapy